The United Kingdom and the United States have secured a significant commercial pact that will maintain zero levies on UK medicine shipments entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these key exports will remain at nothing for a duration of 36 months.
This deal is in response to previous warnings to significantly raise tariffs on patented drug imports, with increases discussed as high as 100%.
"This agreement with the UK strengthens the worldwide climate for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release noted.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's largest export categories to the America, which is by far the primary destination for leading UK drugmakers.
Export figures show that in the year to the end of September, the UK sold drugs worth billions to the US. This value made up nearly one-fifth of British export trade in that period.
"This deal secures work, increases funding and facilitates the UK to establish itself as a global hub for life sciences," a government official stated.
Detailed NHS Changes
The deal involves several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase total NHS spending on medicines from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
This agreement follows a protracted dispute between the sector and the UK government over drug pricing and approval rates.
These tensions were intensified by claims that American customers were charged significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been halted or scrapped, while substantial expansions have been announced toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
